Cover Image

Corrigendum: Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China

Saved in:

Bibliographic Details
Main Authors:	Jia Liu (Author), Lidan Cao (Author), Jing Wu (Author)
Format:	Book
Published:	Frontiers Media S.A., 2022-11-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China
by: Jia Liu, et al.
Published: (2022)

Cost analysis of lurasidone for the treatment of schizophrenia in adolescents and adults within the United Kingdom
by: Amy Dymond, et al.
Published: (2022)

Lurasidone for the treatment of schizophrenia in adult and paediatric populations
by: Teresa Guilera, et al.
Published: (2023)

Clinical potential of lurasidone in the management of schizophrenia
by: Samalin L, et al.
Published: (2011)

Lurasidone for the Treatment of Schizophrenia: Design, Development, and Place in Therapy
by: Miura I, et al.
Published: (2023)

Update on the development of lurasidone as a treatment for patients with acute schizophrenia
by: Yasui-Furukori N
Published: (2012)

Identification of clinical phenotypes in schizophrenia: the role of lurasidone
by: Marco Andrea Riva, et al.
Published: (2021)

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal Cancer
by: Meiyu Wu, et al.
Published: (2022)

Antipsychotic treatments; Focus on lurasidone
by: Tomiki eSumiyoshi
Published: (2013)

Management of bipolar I depression: clinical utility of lurasidone
by: Findlay LJ, et al.
Published: (2015)

Cost-utility analysis of using paliperidone palmitate in schizophrenia in China
by: Rui Luo, et al.
Published: (2023)

Hospitalization outcomes in patients with schizophrenia after switching to lurasidone or quetiapine: a US claims database analysis
by: John W. Newcomer, et al.
Published: (2018)

Corrigendum: Increased Appetite Plays a Key Role in Olanzapine-Induced Weight Gain in First-Episode Schizophrenia Patients
by: Jing Huang, et al.
Published: (2020)

Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
by: Ye Peng, et al.
Published: (2022)

Towards full recovery with lurasidone: effective doses in the treatment of agitation, affective, positive and cognitive symptoms in schizophrenia, and dual psychosis
by: María Teresa Guarro Carreras, et al.
Published: (2024)

The Cost Effectiveness of Donafenib Compared With Sorafenib for the First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma in China
by: Rui Meng, et al.
Published: (2022)

First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis
by: Qiao Liu, et al.
Published: (2021)

Cost-Effectiveness of Bevacizumab Biosimilar LY01008 Combined With Chemotherapy as First-Line Treatment for Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small Cell Lung Cancer
by: Xia Luo, et al.
Published: (2022)

Efficacy, tolerability, and safety of lurasidone for acute schizophrenia: A systematic review and network meta‐analysis of phase 3 trials in Japan
by: Taro Kishi, et al.
Published: (2020)

Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China
by: Yanhong Liu, et al.
Published: (2024)

Corrigendum: The value of second-line anti-HER2 therapy in metastatic HER-2 positive patients: a cost-effectiveness analysis in China
by: Lu Li, et al.
Published: (2024)

Microneedle-Assisted Transdermal Delivery of Lurasidone Nanoparticles
by: Ariana Radmard, et al.
Published: (2024)

Dynamic zero-COVID strategy in controlling COVID-19 in Shanghai, China: A cost-effectiveness analysis
by: Chongqing Tan, et al.
Published: (2023)

Sacubitril-valsartan for the treatment of hypertension in China: A cost-utility analysis based on meta-analysis of randomized controlled trials
by: Yake Lou, et al.
Published: (2022)

Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China
by: Yamin Shu, et al.
Published: (2022)

Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain [Corrigendum]
by: Mareque M, et al.
Published: (2021)

Performance of PRISM III, PELOD-2, and P-MODS Scores in Two Pediatric Intensive Care Units in China
by: Lidan Zhang, et al.
Published: (2021)

Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China
by: Taihang Shao, et al.
Published: (2022)

The effects of emotional labor and competency on job satisfaction in nurses of China: A nationwide cross-sectional survey
by: Xinjuan Wu, et al.
Published: (2018)

Drug Pricing of Domestic Anti-PD-L1 Antibody Adebrelimab: Cost-Effectiveness Analysis of the First-Line ES-SCLC Treatment in China
by: Zhou D, et al.
Published: (2023)

Tislelizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis
by: Zhiwei Zheng, et al.
Published: (2024)

Cost-effectiveness analysis of sugemalimab vs. placebo, in combination with chemotherapy, for treatment of first-line metastatic NSCLC in China
by: Wei Li, et al.
Published: (2022)

Lurasidone‐induced hyperosmolar hyperglycemic syndrome: A case report
by: Shota Hanyu, et al.
Published: (2022)

Cost-effectiveness of pembrolizumab plus chemotherapy vs. chemotherapy as first-line treatment for advanced biliary tract cancer in China and the US
by: Xianmei Luo, et al.
Published: (2024)

Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma
by: Ting Zhou, et al.
Published: (2022)

Increased Appetite Plays a Key Role in Olanzapine-Induced Weight Gain in First-Episode Schizophrenia Patients
by: Jing Huang, et al.
Published: (2020)

Hospitalization costs among immobile patients with hemorrhagic or ischemic stroke in China: a multicenter cross-sectional study
by: Hongpeng Liu, et al.
Published: (2020)

Cost-Effectiveness of Tislelizumab Versus Docetaxel for Previously Treated Advanced Non-Small-Cell Lung Cancer in China
by: Jinhong Gong, et al.
Published: (2022)

Cost-effectiveness analysis of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal squamous-cell carcinoma in China
by: Shixian Liu, et al.
Published: (2023)

Use of electroconvulsive therapy in adolescents with schizophrenia in China
by: Shuai Wang, et al.
Published: (2018)